Patient Support Services Contact Us
At Coherus, we put patients first. We're dedicated to improving lives by expanding access to biologics. Our robust pipeline is bringing high-value treatments to patients in need. We have the assets, expertise, and insights to bring high-quality products to patients around the world.
| Product/ Candidate | Description | Pre-Clinical | Phase 1/2 | Phase 3/ BLA Enabling | Approved | Status |
|---|
| Product/ Candidate | Description | Pre-Clinical | Phase 1/2 | Phase 3 /BLA Enabling | Approved | Status |
|---|---|---|---|---|---|---|
| UDENYCA® | pegfilgrastim biosimilar | Approved by the US Food and Drug Administration and European Commission |
| Product/ Candidate | Description | Pre-Clinical | Phase 1/2 | Phase 3/ BLA Enabling | Approved | Status |
|---|---|---|---|---|---|---|
| CHS-1420 | adalimumab biosimilar | Phase 3 clinical studies in psoriasis completed | ||||
| CHS-0214 | etanercept biosimilar | Phase 3 clinical studies in psoriasis and RA completed |
| Product/ Candidate | Description | Pre-Clinical | Phase 1/2 | Phase 3/ BLA Enabling | Approved | Status |
|---|---|---|---|---|---|---|
| Licensed from Bioeq | ranibizumab biosimilar | Phase 3 clinical studies in wet AMD completed | ||||
| CHS-2020 | aflibercept biosimilar | Pre-clinical development |
| Product/ Candidate | Description | Pre-Clinical | Phase 1/2 | Phase 3/ BLA Enabling | Approved | Status |
|---|---|---|---|---|---|---|
| CHS-131 | Selective PPAR-gamma modulator | Initiating Phase 2 studies in NASH |